BIND Therapeutics (BIND) Appoints Jonathan Yingling, Ph.D., As Chief Scientific Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®, today announced the appointment of Jonathan Yingling, Ph.D., as Chief Scientific Officer. In this position, Dr. Yingling will be responsible for leading BIND's research and development efforts to identify and pursue new product opportunities where the unique attributes of ACCURINs can be leveraged to provide meaningful improvements in patient care.

Suggested Articles

Bayer's finerenone beat placebo at slowing kidney disease and cut the risk of heart attacks and strokes in diabetic kidney disease patients.

The National Institute of Allergy and Infectious Diseases is launching a new clinical trials network for COVID-19.

While Sanofi is looking to move more of its R&D in-house, there is still room for deals, and today it’s penned a big one with Fierce 15 winner Kymera